ClinicalTrials.gg
WithdrawnNCT02603068Updated Feb 9, 2016

Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis

A Phase 2 interventional study of Oral treprostinil in Pulmonary Hypertension and Pulmonary Fibrosis, sponsored by United Therapeutics. Withdrawn at 7 sites in United States. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2016-02-09.

Sponsored by United Therapeutics · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Study design was inadequate and would not achieve study endpoints

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies testing treprostinil in Hypertension, Pulmonary — 4 open to participants now, 4 under way, 1 of them phase 3. treprostinil · Hypertension, Pulmonary.

Enrollment
33rd of 37
0 · median 32
Started
2016
with 2 others
Phase 2
7 of 38
none open now
Registered
20th of 38
by date
Lead sponsor
25 of 38
United Therapeutics

Among the 38 studies testing treprostinil in Hypertension, Pulmonary, this one is the 33rd largest by enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2016, is one of 7 in phase 2, and was the 20th registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

4 of the 38 studies testing treprostinil in Hypertension, Pulmonary are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About treprostinil

treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 164 Hypertension, Pulmonary studies recruiting now, 99 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing treprostinil in Hypertension, Pulmonary, or all of them as a file.
02

Study summary

This multicenter, randomized, open-label study will assess the safety and efficacy of oral treprostinil in subjects diagnosed with pulmonary hypertension associated with pulmonary fibrosis.

Read the detailed description

This study will evaluate how oral treprostinil can affect pulmonary vascular resistance, as assessed by right heart catheterization, and exercise capacity, as assessed by the Six-Minute Walk Test. This is a 16-week study that will involve at least 10 clinical trial centers. The expected enrollment period is around 24 months and 52 subjects will be entered into the study.

03

Conditions studied

  • Pulmonary Hypertension
  • Pulmonary Fibrosis
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily gives
  • Must meet criteria for lung transplant referral but is not required to be on an active lung transplant list
  • Stable and significant diffuse parenchymal lung disease with a diagnosis of interstitial lung disease
  • 6MWD greater than or equal to 75 meters
  • Right heart catheterization with a mean pulmonary arterial pressure >= 30 mgHg, pulmonary capillary wedge pressure \<= 15 mmHg and pulmonary vascular resistance > 240 dynes
  • Echo-Doppler examination showing evidence of right ventricular dysfunction and normal left diastolic ventricular function
  • Either not receiving any PAH-approved oral therapy, or is receiving monotherapy (ERA, PDE-5I, or riociguat) for > 60 days and receiving a stable dose for > 30 days prior to enrollment
  • Able to communicate effectively with study personnel and will to be cooperative with protocol requirements

Exclusion criteria

Exclusion Criteria:

  • History of repaired or unrepaired congenital heart disease
  • Received prostanoid therapy in the past 30 days, or has shown an intolerance or lack of efficacy to prostanoid therapy resulting in discontinuation or inability to titrate prostacyclins
  • Diagnosis of sarcoidosis
  • History of thromboembolic disease
  • Chronic renal insufficiency
  • Pregnancy or lactating
  • Currently receiving an drug, has an investigational device in place, or has participated in an investigational drug or device study within 30 days prior to Screening
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Individual Maximum Tolerated Dose (iMTD)

    Subjects are allowed to titrate oral treprostinil up to a maximum dose of 12 mg TID.

    Drug: Oral treprostinil

  • Experimental
    Fixed Dose (FD)

    Subjects are allowed to titrate oral treprostinil up to a maximum dose of 1 mg TID.

    Drug: Oral treprostinil

Interventions

  • Oral treprostinil will be administered as TID dosing for up to 16 Weeks.

    Also known as: Orenitram

06

What researchers measure

Primary outcomes

  1. Change in pulmonary vascular resistance (PVR)

    Change in PVR between iMTD and fixed dose groups

    Time frame: Baseline to Week 16

Secondary outcomes

  1. Change in Six-minute walk distance (6MWD)

    Change in 6MWD between iMTD and fixed dose groups

    Time frame: Baseline to Week 16

  2. Change in N-terminal pro-brain natriuretic peptide (NT-ProBNP)

    Change in NT-ProBNP between iMTD and fixed dose groups

    Time frame: Baseline to Week 16

07

Study locations

7 sites
  • Banner University Medical Center Phoenix Advanced Lung Disease
    Phoenix, Arizona 85006, United States
  • University of California, Los Angeles - Pulmonary Division
    Los Angeles, California 90024, United States
  • University of California - Davis Medical Group
    Sacramento, California 95817, United States
  • Emory University Hospital
    Atlanta, Georgia 30322, United States
  • Johns Hopkins University
    Baltiomore, Maryland 21205, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • CLC Pulmonary Hypertension Clinic Division of Pulmonary, Allergy and Critical Care Medicine UPMC
    Pittsburgh, Pennsylvania 15213, United States
08

References and documents

Individual participant data

Plan to share: No — Study is withdrawn. There is no data to share.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2016, a primary completion of Apr 2018 and a completion of Jul 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2015
First posted
Nov 11, 2015
Start
Feb 2016
Primary completionEst.
Apr 2018
CompletionEst.
Jul 2018
Last update
Feb 9, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02603068
Responsible party
Sponsor
First posted
Nov 11, 2015
Start date
Feb 2016
Primary completion
Apr 2018 (estimated)
Completion
Jul 2018 (estimated)
Last update
Feb 9, 2016

Study contacts

Rajan Saggar, MD
principal investigator · University of California, Los Angeles - Pulmonary Division

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion